Infusing umbilical cord blood – a readily available source of stem cells – safely and effectively treated 44 children born with various non-cancerous genetic disorders, including sickle cell, thalassemia, Hunter syndrome, Krabbe disease, MLD, and an array of immune deficiencies.
Moffitt Cancer Center researchers want to learn more about how PI3K inhibitor therapy works with the body’s immune system to determine if there are ways to predict or mitigate associated adverse effects. Their findings were published in the July 14 issue of Blood Advances, a journal of the American Society of Hematology.
Stay-at-home orders during the COVID-19 pandemic has resulted in an increased need for blood and platelets. Rutgers Cancer Institute expert shares why right now is an important time to donate blood to ensure a sufficient blood supply for patients in need.
An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.
A research team is the first in Texas to investigate whether plasma from COVID-19 survivors can be used in outpatient settings to prevent the onset and progression of the virus in two new clinical trials at UTHealth.
Researchers at University of California San Diego School of Medicine and UC San Diego Health have launched a clinical trial to assess the safety and efficacy of convalescent plasma (CP) to prevent COVID-19 after a known exposure to the virus.
A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a blood test involving these vesicles might be used to diagnose cancer in the future, avoiding the need for invasive surgical biopsies.
A blood biomarker in people who have had concussions may be just as accurate at predicting the severity of the injury and how long it will last as biomarkers that are obtained through more expensive and invasive tests, according to a study published in the July 8, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
If you have sickle cell disease, you are at higher risk than the general population for severe complications from COVID-19.
New findings led by Yale Cancer Center researchers and experts across several medical specialties at Yale identify a leading mechanism behind the pathophysiology of Covid-19 and pinpoint a biological marker for the mechanism that may aid in treating these patients.
Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists. The researchers found that inflammatory proteins produced during infection significantly alter the function of platelets, making them “hyperactive” and more prone to form dangerous and potentially deadly blood clots.
Scientists have new evidence that overactive neutrophils--a common type of circulating immune cell--may drive the life-threatening blood clots and inflammation that occur in some patients with COVID-19.
An overactive defense response may lead to increased blood clotting, disease severity, and death from COVID-19. A phenomenon called NETosis—in which infection-fighting cells emit a web-like substance to trap invading viruses—is part of an immune response that becomes increasingly hyperactive in people on ventilators and people who die from the disease.
Kawasaki disease, sometimes called Kawasaki syndrome, is a serious inflammation of the blood vessels which affects young children, often under 5 years of age. Marked by fever, swelling and other symptoms, it can lead to coronary artery aneurysms in approximately 25% of cases if untreated.
Edward J. Benz, Jr., MD, President and CEO Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School, has received the 2020 ASH Award for Leadership in Promoting Diversity.
A new study by researchers at UCSF Benioff Children’s Hospitals and St. Jude Children’s Research Hospital has identified what they believe to be a key reason behind patients’ treatment-resistance in the rare inflammatory disorder HLH. The finding could offer additional insights into other immune conditions, including a type of childhood leukemia and the severe inflammation response in some children with COVID-19.
Tickets are on sale now for a fun-filled evening of vasculitis awareness and entertainment. Don’t miss it!
New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center’s Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease (GVHD) during allogeneic blood/marrow transplant (BMT) — a potentially curative treatment for selected patients with hematologic disorders — can be decreased using an existing class of drugs called beta adrenergic agonists.
Scientists at St. Jude Children’s Research Hospital, UCSF Benioff Children’s Hospitals and Baylor College of Medicine are investigating how to best treat hemophagocytic lymphohistiocytosis (HLH), a rare immune disorder. Their work, appearing as an advance online publication today in Blood, details how combining two drugs may be a good treatment for HLH.
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19.
One of the first studies to investigate the outcome of COVID-19 infection in patients with blood cancer has been conducted by clinical researchers from Queen Mary University of London and Barts Health NHS Trust.
The Vasculitis Foundation rolls out new podcast series, designed to educate and provide insight into rare, autoimmune blood vessel disorder.
High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS).
Nearly a century after insulin was discovered, an international team of researchers including University of Utah Health scientists report that they have developed the world’s smallest, fully functional version of the hormone, one that combines the potency of human insulin with the fast-acting potential of a venom insulin produced by predatory cone snails. The finding, based on animal studies, could jumpstart the development of insulin treatments capable of improving the lives of those with diabetes.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML harboring an IDH1 mutation who have historically had few treatment options.
A blood test may help researchers understand which people may take years to recover from concussion, according to a study published in the May 27, 2020 online issue of Neurology®, the medical journal of the American Academy of Neurology. The study looked at a biomarker called neurofilament light chain, a nerve protein that can be detected in the blood when nerve cells are injured or die.
A new landmark study by researchers at the University of Maryland School of Medicine (UMSOM) found that patients with a vascular condition, called abdominal aortic aneurysm, received no benefits from taking a common antibiotic drug to reduce inflammation.
Red blood cells sometimes rupture when blood is sent through faulty equipment, such as a dialysis machine. This is called hemolysis. Hemolysis also can occur during blood work when blood is drawn too quickly through a needle, leading to defective laboratory samples. University of Delaware mechanical engineer Tyler Van Buren and collaborating colleagues at Princeton University have developed a method to monitor blood damage in real-time.
A blood test may help predict which people with multiple sclerosis (MS) will get worse during the following year, according to a study published in the May 20, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Researchers trace the evolutionary origins of hemoglobin by resurrecting ancient proteins from more than 400 million years ago
When researchers from the University of Colorado Anschutz Medical Campus, Aurora, used a combination of two specific blood-clotting tests, they found critically ill patients infected with Coronavirus Disease 2019 (COVID-19) who were at high risk for developing renal failure, venous blood clots, and other complications associated with blood clots, such as stroke.
Researchers from Rutgers Cancer Institute of New Jersey along with collaborators from Princeton University identify a new drug that has therapeutic effect against the aggressive hematological disease T-cell acute lymphoblastic leukemia.
Research could change standard of care protocols to prevent clotting associated with coronavirus
The Race is On! That’s the theme for Vasculitis Awareness Month 2020, which runs May 1 through May 31, 2020, and shines a spotlight on vasculitis—a rare, but often serious autoimmune blood vessel disorder.
美国食品和药物管理局(FDA)于4月3日周五宣布，Mayo Clinic 将作为牵头机构，为新冠肺炎 (COVID-19) 重症和危重症住院患者或有较高风险发展成重症或危重症患者的人士提供支持，供应试验性痊愈者血浆。点击此处查看公告详情。
A Mayo Clinic será a instituição líder em fornecer acesso coordenado ao plasma convalescente experimental para pacientes hospitalizados com COVID-19 severa ou com risco de morte, ou para os que tem alto risco de progressão para doença severa ou com risco de morte. A Administração de Drogas e Alimentos dos Estados Unidos (FDA, por suas siglas em inglês) anunciou a designação na sexta-feira, dia 3 de abril.
Mayo Clinic será la primera institución en brindar acceso coordinado al plasma experimental procedente de personas convalecientes a los pacientes hospitalizados por COVID-19 severo o potencialmente mortal y a quienes tienen riesgo de avanzar hacia esos estados de la enfermedad. La Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) anunció este nombramiento el día viernes 3 de abril.
Montefiore Health System, Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma—taken from people who have recovered from COVID-19—is effective in treating the disease.
A clinical trial now underway is looking at whether blood plasma donated by people recovered from 2019 coronavirus disease (COVID-19) could be used to treat other people with the pandemic virus.
In this week’s Biomicrofluidics, a method to characterize the shape recovery of healthy human RBCs flowing through a microfluidic constricted channel is reported. This investigation revealed a coupling between the cell’s mechanical properties and the hydrodynamic properties of the flow. In addition, the method could distinguish between healthy red blood cells and those infected by the malaria parasite. This suggests a possible new technique for diagnosing disease.
Researchers from the UCLA Jonsson Comprehensive Cancer Center received a $2.8 million, five-year grant from the National Cancer Institute to help develop a blood-based test to improve the selection and prioritization for patients with liver cancer who need a liver transplantation.
Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study.
As the number of COVID-19 cases in the U.S. surpasses 800,000, many Americans want to know if recovered patients have immunity to the novel coronavirus. The answer could come from an antibody test. While these tests are commonly used to tell if someone is immune to diseases such as measles or chickenpox, they're not yet widely available for COVID-19. But it's not clear what the results would mean.
New study explores the connection between levels of a type of destructive white blood cell, known as a neutrophil, with the severity of COVID-19.
New research suggests that men with high blood pressure may have reduced blood vessel dilation in the legs and that a form of high-intensity interval exercise training improves blood vessel function in this population.
Blood Donation Network, Vitalant and Hackensack Meridian Mountainside Medical Center are partnering to begin collecting plasma from recovered COVID-19 patients to help those currently suffering from the coronavirus. People who have fully recovered from COVID-19 have antibodies in their plasma—known as convalescent plasma—that can attack the virus and be used as treatment for patients with life-threatening symptoms.
High-altitude adaptations in the Himalayas may lower risk for some chronic diseases, according to a research team including faculty from Binghamton University, State University of New York, the University of New Mexico, and the Fudan University School of Life Sciences.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right